Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

Descrizione del progetto

Combattere la farmacoresistenza nella LMA

La leucemia mieloide acuta (LMA) è un cancro letale con bassi tassi di sopravvivenza, per lo più dovuti alla farmacoresistenza. Nonostante i progressi delle terapie mirate, molti pazienti presentano una ricaduta. Una sfida fondamentale consiste nel capire come le alterazioni epigenetiche nella LMA consentano alle cellule tumorali di sviluppare resistenza sotto pressione farmacologica. Il progetto SC-Plasticity, finanziato dal CER, utilizzerà in tale ambito tecniche innovative di sequenziamento a singola cellula, come scRaCH-seq, per analizzare come le mutazioni dei regolatori epigenetici influenzino le risposte alla terapia. Studiando il modo in cui le modifiche epigenetiche influiscono sulla sensibilità ai farmaci, questa ricerca potrebbe aprire la strada a nuove strategie per superare la resistenza ai farmaci e migliorare i risultati del trattamento nella LMA.

Obiettivo

Novel targeted therapies are increasingly applied against a wide range of cancers. Although such agents can induce cures, most patients suffer from relapsed disease.

Acute myeloid leukaemia (AML) is a prime example of a deadly disease, but we have a chance to dramatically improve outcomes if we can better understand resistance mechanisms against targeted agents that are transforming AML treatment, such as the BCL2 inhibitor venetoclax. AML is characterised by profound alterations in the epigenome that are correlated with poor survival. I therefore hypothesise that targeted drug pressure induces epigenetic plasticity that allows cancer cells to sample alternate chromatin or transcriptional states, a subset of which confer drug resistance. A major challenge is to define how mutations of epigenetic regulators in AML affect therapy responses due to clonal heterogeneity. To address this challenge, I will use and further develop my recently published single-cell Rapid Capture Hybridization sequencing (scRaCH-seq) method to link the genotype of expressed genes to transcription and methylation profiles of thousands of single cells. In this research proposal, I aim to (1) develop a new method linking epigenetic landscape, genotype and transcriptome at a single-cell level and define the impact of treatment on these interactions. (2) Analyse the genome-wide impact of epigenetic therapies. (3) Define the association between drug sensitivity and epigenetic modifications regulating pro-survival genes. To achieve my goals, I will apply my novel single-cell multiomics to samples from AML patients treated with venetoclax alone or in combination with epigenetic therapies and apply state-of-the-art technologies to established laboratory models.

Our new approaches to fully understand the relationship between the genome, epigenome and transcriptome will advance fundamental biology. This has the potential to yield new therapeutic strategies to prevent and overcome resistance.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2023-STG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

STICHTING AMSTERDAM UMC
Contributo netto dell'UE
€ 1 882 440,00
Costo totale
€ 1 882 440,00

Beneficiari (1)